Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

ABSTRACT:

Background

In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs).

Methods

Eligible patients received daily temozolomide (50 mg/m2) continuously until progression. The primary endpoint was progression-free survival rate at 6 months in the glioblastoma cohort (N = 37). In an exploratory analysis, 10 additional recurrent grade III MG patients were enrolled. Correlative studies included evaluation of 76 frequent mutations in glioblastoma (iPLEX assay, Sequenom) aiming at establishing the frequency of potentially "drugable" mutations in patients entering recurrent MG clinical trials.

Results

Among glioblastoma patients, median age was 56 y; median Karnofsky performance score (KPS) wa

SUBMITTER: Omuro A 

PROVIDER: S-EPMC3548585 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature